GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroGen Inc (NAS:FGEN) » Definitions » Cyclically Adjusted PS Ratio

FibroGen (FibroGen) Cyclically Adjusted PS Ratio : 0.43 (As of May. 16, 2024)


View and export this data going back to 2014. Start your Free Trial

What is FibroGen Cyclically Adjusted PS Ratio?

As of today (2024-05-16), FibroGen's current share price is $1.2002. FibroGen's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $2.78. FibroGen's Cyclically Adjusted PS Ratio for today is 0.43.

The historical rank and industry rank for FibroGen's Cyclically Adjusted PS Ratio or its related term are showing as below:

FGEN' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.14   Med: 0.66   Max: 8.47
Current: 0.42

During the past years, FibroGen's highest Cyclically Adjusted PS Ratio was 8.47. The lowest was 0.14. And the median was 0.66.

FGEN's Cyclically Adjusted PS Ratio is ranked better than
92.19% of 512 companies
in the Biotechnology industry
Industry Median: 5.535 vs FGEN: 0.42

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

FibroGen's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.565. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $2.78 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


FibroGen Cyclically Adjusted PS Ratio Historical Data

The historical data trend for FibroGen's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroGen Cyclically Adjusted PS Ratio Chart

FibroGen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 5.52 0.32

FibroGen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.40 0.93 0.31 0.32 0.85

Competitive Comparison of FibroGen's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, FibroGen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


FibroGen's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FibroGen's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where FibroGen's Cyclically Adjusted PS Ratio falls into.



FibroGen Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

FibroGen's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1.2002/2.78
=0.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

FibroGen's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, FibroGen's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.565/131.7762*131.7762
=0.565

Current CPI (Mar. 2024) = 131.7762.

FibroGen Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 1.903 100.560 2.494
201409 0.245 100.428 0.321
201412 0.273 99.070 0.363
201503 0.275 99.621 0.364
201506 1.753 100.684 2.294
201509 0.322 100.392 0.423
201512 0.397 99.792 0.524
201603 0.455 100.470 0.597
201606 1.294 101.688 1.677
201609 0.479 101.861 0.620
201612 0.561 101.863 0.726
201703 0.460 102.862 0.589
201706 0.435 103.349 0.555
201709 0.534 104.136 0.676
201712 0.374 104.011 0.474
201803 0.385 105.290 0.482
201806 0.525 106.317 0.651
201809 0.343 106.507 0.424
201812 1.270 105.998 1.579
201903 0.278 107.251 0.342
201906 2.088 108.070 2.546
201909 0.381 108.329 0.463
201912 0.091 108.420 0.111
202003 0.277 108.902 0.335
202006 0.479 108.767 0.580
202009 0.470 109.815 0.564
202012 0.713 109.897 0.855
202103 0.419 111.754 0.494
202106 0.264 114.631 0.303
202109 1.681 115.734 1.914
202112 0.178 117.630 0.199
202203 0.654 121.301 0.710
202206 0.319 125.017 0.336
202209 0.168 125.227 0.177
202212 0.365 125.222 0.384
202303 0.382 127.348 0.395
202306 0.453 128.729 0.464
202309 0.409 129.860 0.415
202312 0.275 129.419 0.280
202403 0.565 131.776 0.565

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


FibroGen  (NAS:FGEN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


FibroGen Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of FibroGen's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


FibroGen (FibroGen) Business Description

Industry
Traded in Other Exchanges
Address
409 Illinois Street, San Francisco, CA, USA, 94158
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.
Executives
Jeffrey William Henderson director 7000 CARDINAL PLACE, DUBLIN OH 43017
Enrique A Conterno director, officer: Chief Executive Officer LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Thane Wettig officer: Chief Commercial Officer C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Christine Chung officer: SVP, China Operations C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Jeffrey L Edwards director 2525 DUPONT DR, IRVINE CA 92612
Aoife Brennan director 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Benjamin Cravatt director C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Suzanne Blaug director C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Maykin Ho director C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
James A Schoeneck director C/O DEPOMED, INC., 1360 O'BRIEN DRIVE, MENLO PARK CA 94025
Mark Eisner officer: Incoming Chief Medical Officer C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Juan Graham officer: Chief Financial Officer C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Kearns Thomas F Jr director P O BOX 587, WARSAW IN 46581-0587
Pat Controneo officer: VP, Finance and CFO C/O FIBROGEN, INC., 409 ILLINOIS ST.,, SAN FRANCISCO CA 94158
Kalevi Kurkijarvi director C/O FIBROGEN, INC., 409 ILLINOIS ST.,, SAN FRANCISCO CA 94158